Abstract
MicroRNAs (miRNAs), which are highly conserved, non-coding endogenous RNA and nearly ~22 nucleotides (nt) in length, have been widely reported to play the crucial roles in a number of pathological processes, most notably cancer. Hitherto, accumulating evidence has demonstrated that miRNAs are involved in mediating several cancer-related pathways linked to Programmed cell death (PCD), indicating that miRNAs may function as the key regulators in apoptosis and autophagy of cancer. In this review, we present a brief outline of the discovery, biosynthetic pathway and regulatory mechanisms of miRNAs, and further elucidate how miRNAs can regulate apoptotic and autophagic pathways as oncogenes or tumor suppressor genes in cancer. Together, these inspiring findings would help cancer biologists and clinicians uncover the mysterious landscape of miRNAs, thereby ultimately harnessing the miRNA-targeted PCD pathways for future cancer therapeutics.
Keywords: Apoptosis, autophagy, cancer, MicroRNA (miRNA), Programmed Cell Death (PCD)
Current Chemical Biology
Title:MicroRNA Regulation of Programmed Cell Death Pathways in Cancer
Volume: 6 Issue: 1
Author(s): Miao Ming, Xu Zhao, Zi-yi Zhao, Bo Liu and Jin-ku Bao
Affiliation:
Keywords: Apoptosis, autophagy, cancer, MicroRNA (miRNA), Programmed Cell Death (PCD)
Abstract: MicroRNAs (miRNAs), which are highly conserved, non-coding endogenous RNA and nearly ~22 nucleotides (nt) in length, have been widely reported to play the crucial roles in a number of pathological processes, most notably cancer. Hitherto, accumulating evidence has demonstrated that miRNAs are involved in mediating several cancer-related pathways linked to Programmed cell death (PCD), indicating that miRNAs may function as the key regulators in apoptosis and autophagy of cancer. In this review, we present a brief outline of the discovery, biosynthetic pathway and regulatory mechanisms of miRNAs, and further elucidate how miRNAs can regulate apoptotic and autophagic pathways as oncogenes or tumor suppressor genes in cancer. Together, these inspiring findings would help cancer biologists and clinicians uncover the mysterious landscape of miRNAs, thereby ultimately harnessing the miRNA-targeted PCD pathways for future cancer therapeutics.
Export Options
About this article
Cite this article as:
Ming Miao, Zhao Xu, Zhao Zi-yi, Liu Bo and Bao Jin-ku, MicroRNA Regulation of Programmed Cell Death Pathways in Cancer, Current Chemical Biology 2012; 6 (1) . https://dx.doi.org/10.2174/2212796811206010053
DOI https://dx.doi.org/10.2174/2212796811206010053 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
P-glycoprotein Inhibition: The Past, the Present and the Future
Current Drug Metabolism New Perspective on the Dual Functions of Indirubins in Cancer Therapy and Neuroprotection
Anti-Cancer Agents in Medicinal Chemistry Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies
Current Topics in Medicinal Chemistry Targeting the Perpetrator: Breast Cancer Stem Cell Therapeutics
Current Drug Targets SUMOylation Regulation of Retina Development and Functions
Current Molecular Medicine Classical to Current Approach for Treatment of Psoriasis: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Review of Procedures Used for the Extraction of Anti-Cancer Compounds from Tropical Plants
Anti-Cancer Agents in Medicinal Chemistry Should We Develop an Inhaled Anti-pneumococcal Vaccine for Adults?
Current Medicinal Chemistry - Anti-Infective Agents Recent Advances in the Development of Dual Topoisomerase I and II Inhibitors as Anticancer Drugs
Current Medicinal Chemistry Polo-Like Kinases Inhibitors
Current Medicinal Chemistry Novel Drug Targets in Malaria Parasite with Potential to Yield Antimalarial Drugs with Long Useful Therapeutic Lives
Current Pharmaceutical Design Stem Cell Ageing and Apoptosis
Current Pharmaceutical Design TGF-β1 Signalling, Connecting Aberrant Inflammation and Colorectal Tumorigenesis
Current Pharmaceutical Design Small Molecules in Cancer Therapy: Cytotoxics and Molecularly Targeted Agents
Current Signal Transduction Therapy Sumoylation Pathway as Potential Therapeutic Targets in Cancer
Current Molecular Medicine Neutral Actions of Raltegravir on Adipogenesis, Glucose Metabolism and Lipolysis in 3T3-L1 Adipocytes
Current HIV Research Treatment of Acute Leukaemias with Monoclonal Antibodies: Current Status and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting BCR-ABL Oncoprotein for Leukemia Therapy: Current Biotechnology and Future Perspectives
Current Biotechnology The Genetic Variants of IKZF1 Gene Linked with the Growing Risk of Childhood Acute Lymphoblastic Leukaemia
Current Molecular Medicine